RUNX1 and T-cell non-Hodgkin lymphoma: In contrast to this catalogue of evidence of dominant oncogenic activity in lymphomagenesis, Runx1 deficient cells in chimeric mice develop T-cell lymphomas after treatment with ENU [17], suggesting that loss of Runx1 activity can also predispose to lymphoid malignancy.